Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7806881 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7806881: Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will receive single doses of RO7806881, at 8 dose levels across 9 different cohorts (A1-A9) including one optional SAD cohort of East Asian participants (Cohort A9). |
| Placebo: SAD | PLACEBO_COMPARATOR | Participants will receive single doses of placebo, matched to each of the 8 dose levels of RO7806881. |
| RO7806881: Multiple Ascending Doses (MAD) | EXPERIMENTAL | Participants will receive multiple doses of RO7806881, at 4 dose levels across 4 different cohorts (B1-B4), per the predefined dosing regimen. |
| Placebo: MAD | PLACEBO_COMPARATOR | Participants will receive multiple doses of placebo, matched to each of the 4 dose levels of RO7806881, per the predefined dosing regimen. |
| Name | Type | Description |
|---|---|---|
| RO7806881 | DRUG | RO7806881 will be administered as per the schedule specified in the protocol. |
| Placebo | DRUG | Placebo will be administered as per the schedule specified in the protocol. |
Inclusion Criteria: * Participants must be males or females who are overtly healthy as determined by medical evaluation * Participants must have body weight (BW) ≥ 40 kilograms (kg) (not applicable to Cohort A9) and body mass index (BMI) within the range 18-32 kilograms per square meter (kg/m\^2) (...
RO7806881 is an investigational small molecule being developed by Roche Holding AG (ticker: RHHBY). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
RO7806881 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial to assess the drug's safety and other properties in healthy participants.
RO7806881 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants to evaluate the drug's safety, tolerability, and how it is processed by the body.
RO7806881 is being studied in one active Phase 1 clinical trial, identified as NCT07271693. This trial is titled 'A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants' and is currently recruiting in New Zealand.
Yes, RO7806881 is being tested in healthy volunteers. The Phase 1 clinical trial NCT07271693 is specifically designed for healthy participants aged 18 years and older. The study is placebo-controlled, double-blind, and randomized, with a total planned enrollment of 128 participants.